Development

Articles

SpringWorks Therapeutics and the Dana-Farber Cancer Institute will conduct further research into the therapeutic potential of combination therapy with nirogacestat and anti-BCMA agents for multiple myeloma.

SpringWorks Therapeutics and Dana-Farber Team Up to Further Evaluate Potential Multiple Myeloma Treatment

Cynthia A. Challener is a contributing editor to Pharmaceutical Technology.

Risk-based decision-making is impacting all aspects of manufacturing quality from raw material supply to facility inspections. 

Tracking API Quality During a Pandemic

Citing undisclosed allegations against Kodak, the DFC placed a hold on a potential $765 million loan to launch US-based API manufacturing.

Allegations Put Kodak Pharmaceuticals Loan on Hold

Several factors must be considered when reformulating APIs for pediatric, geriatric, and other specialty patient populations.

Adapting APIs for Specialty Dosage Forms

Felicity Thomas is Associate Editorial Director of Pharmaceutical Technology, Pharmaceutical Technology Europe, BioPharm International.

The evolution of CDMOs has led to increased investment in new technologies, capabilities, and expertise.


The CDMO Evolution

Nanotechnology is enabling enhanced bioavailability, improved stability, and targeted delivery of challenging APIs.

Facilitating API Delivery with Nanoscale Solutions

New CDMO facility supports early-stage API manufacturing and scale up.

Concept Life Sciences Opens New API Facility in UK

In a deal worth $530 million, the companies will develop and commercialize an anti-epileptic drug candidate in Europe.

SK Biopharmaceuticals, Arvelle Partner on Anti-Epileptic Drug for Europe

Antibody-based drugs offer new mechanisms of action and greater specificity.

Fighting Bacterial Resistance with Biologics

Demand for highly potent APIs continues to rise.

Small-Molecule APIs